Review finds pimavanserin offers little for schizophrenia negative symptoms

If you or someone you love lives with schizophrenia, you know how tough negative symptoms can be. A new review of 1,676 adults looked at adding pimavanserin to standard treatment. The main goal was to see if it helped with negative symptoms like lack of motivation or emotion. The review found no clinically meaningful benefit for these core symptoms. It did see small, statistically significant drops in some overall symptom scores, but those changes were well below what doctors consider meaningful. The drug was generally well tolerated, with no increased risk of serious side effects or discontinuations compared to placebo. However, the evidence was inconsistent across studies, and the populations included were mixed. The review concludes this does not support routine use for negative symptoms. The certainty of the evidence was evaluated with GRADE, and the effects, while detectable, are clinically modest.